首页> 外文期刊>British Journal of Clinical Pharmacology >Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study.
【24h】

Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study.

机译:长期治疗心力衰竭期间的速尿反应性,不依从性和耐药性:一项纵向研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND METHODS: Loop diuretic therapy is an essential part of chronic systolic heart failure (CH)F management, yet response to treatment can be variable. We analysed diuretic responsiveness in 39 stable patients with CHF in the community over 2 years. We measured serum ACE as a marker of adherence to ACE inhibitor therapy and urinary furosemide as a marker of diuretic adherence and action. Patients' clinical outcome was stable and not hospitalized (Group 0); alive but hospitalized (Group 1); or dead during follow up (Group 2). RESULTS: Prescribed furosemide dose was variable (range 20-370 mg generally once daily) and progressive dose increments were common. Failed furosemide adherence (defined as < 10% of a dose excreted in 24 h urine where normal average excretion = 50% of an oral dose) during static prescribed dosing was infrequent relative to all days of therapy; yet was equally common across all outcome groups. Furosemide non-adherence appeared to be independent of non-adherence with ACE inhibitor (as marked by serum ACE activity > 20 U l(-1)) treatment. Furosemide responsiveness (mm of sodium excreted per mg furosemide in urine) showed no relationship to prescribed dose and paradoxically tended to rise in patients with higher basal aldosterone concentrations. Furosemide responsiveness fell by outcome class despite increased dose. Within-patient responsiveness remained relatively constant although highly variable between individuals. CONCLUSIONS: Furosemide responsiveness varied greatly between individuals but was constant within an individual. Non-adherence with furosemide was less common among those who died and appeared to occur at different time points from non-adherence with ACE inhibitor treatment, which was slightly more common in all outcome groups. Patients who died were prescribed higher furosemide doses and had greater furosemide excretion yet had similar sodium excretion. The main factor in response to chronic furosemide therapy was intrarenal diuretic resistance. Gross non-adherence was less important.
机译:背景与方法:利尿剂治疗是慢性收缩性心力衰竭(CH)F管理的重要组成部分,但对治疗的反应可能会有所不同。我们分析了社区2年中39例稳定的CHF患者的利尿反应。我们测量血清ACE作为对ACE抑制剂治疗依从性的标志物,而尿速尿作为利尿剂依从性和作用的标志物。患者的临床结果稳定且未住院(第0组);活着但已住院(第1组);或在随访期间死亡(第2组)。结果:规定的速尿剂量是可变的(通常每天一次,剂量范围为20-370 mg),并且逐渐增加剂量是常见的。相对于整天的治疗,在固定的固定剂量期间很少出现失败的呋塞米依从性(定义为在24小时尿液中排泄的剂量的10%,正常的平均排泄量等于口服剂量的50%)。但在所有结果组中同样普遍。速尿的非依从性似乎与ACE抑制剂的非依从性无关(以血清ACE活性> 20 U l(-1)为标志)。速尿反应性(尿液中每毫克速尿所排出的钠的毫米数)与处方剂量无关,并且在基线醛固酮浓度较高的患者中反常增加。尽管剂量增加,但速尿的反应性因结局类别而下降。尽管个体之间差异很大,但患者内部的反应性仍保持相对恒定。结论:呋塞米的反应性在个体之间差异很大,但在个体内是恒定的。死者中不坚持速尿不服药的发生率较低,并且似乎与不遵守ACE抑制剂治疗的时间不同,这在所有结局组中都更为普遍。死亡患者的速尿剂量较高,速尿排泄量较大,但钠排泄量相似。响应慢性呋塞米治疗的主要因素是肾内利尿剂耐药性。严重的不遵守情况不太重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号